Splitting a Fixed Daily Dose Across Administrations

Why Split a Fixed Daily Dose?

A fixed total daily dose can be administered once or divided into several smaller administrations. In a linear pharmacokinetic model, splitting the dose does not change the total amount administered per day, but it changes how much concentration rises after each administration and how much time is available for elimination before the next one. The resulting steady-state peaks and troughs can therefore differ substantially between schedules.

The comparison here concerns equally spaced, instantaneous intravenous boluses in a linear one-compartment model. It is a controlled comparison: the total daily dose and the patient’s pharmacokinetic parameters are held fixed while the number of administrations changes. This isolates the effect of frequency; it does not establish which regimen is clinically preferable.

Definition: Let \(D\) be the total dose administered in each 24-hour day, \(n\) the positive integer number of equally spaced administrations per day, \(V\) the apparent volume of distribution, and \(k\) the first-order elimination rate constant. Each administration has dose \(D/n\), and the dosing interval is \(\tau=24/n\) hours. Under a one-compartment model with instantaneous boluses and first-order elimination, concentration declines between doses according to \(C(t)=C(0)e^{-kt}\). The elimination half-life is \(t_{1/2}=\ln(2)/k\).

The formulas require constant \(D\), \(V\), and \(k\); linear, time-invariant elimination; equal spacing; and enough repeated doses to reach steady state. Steady state means the concentration profile repeats from one interval to the next. It does not mean concentration is constant during an interval. The model also assumes the bolus reaches the systemic compartment immediately, with no absorption phase or infusion duration.

Deriving the Steady-State Peak and Trough

Let \(C_{\max,ss}\) denote the concentration immediately after a dose at steady state, and \(C_{\min,ss}\) the concentration immediately before the next dose. Over one interval, first-order elimination gives \(C_{\min,ss}=C_{\max,ss}e^{-k\tau}\). The next bolus adds \(D/(nV)\) to the pre-dose concentration. At steady state, the post-dose concentration after that addition must equal the previous interval’s post-dose concentration.

C_{\max,ss}=C_{\min,ss}+\frac{D}{nV} =\left(C_{\max,ss}e^{-k\tau}\right)+\frac{D}{nV}

Rearranging this recurrence gives the peak formula. Multiplying the peak by the fraction remaining after one interval gives the trough formula.

C_{\max,ss}=\frac{D/(nV)}{1-e^{-k\tau}}, \qquad C_{\min,ss}=C_{\max,ss}e^{-k\tau} =\frac{D/(nV)e^{-k\tau}}{1-e^{-k\tau}}, \qquad \tau=\frac{24}{n}

The peak–trough difference follows directly from the recurrence: the peak is the trough plus the concentration increment from one bolus. The peak-to-trough ratio depends on the fraction eliminated between doses. These relationships make the frequency effect transparent.

C_{\max,ss}-C_{\min,ss}=\frac{D}{nV}, \qquad \frac{C_{\max,ss}}{C_{\min,ss}}=e^{k\tau}

At a fixed daily dose, increasing \(n\) reduces the concentration increment per administration, \(D/(nV)\), and shortens \(\tau\). Both changes tend to reduce peak–trough fluctuation: the peak is lower and the trough is higher. The precise values still depend on elimination speed relative to the dosing interval; a given frequency change has a larger effect when appreciable elimination would otherwise occur between administrations.

Worked Example: Comparing Once-, Twice-, and Three-Times-Daily Dosing

Suppose a hypothetical drug is given as an instantaneous bolus, with a fixed daily dose of \(D=300\) mg, \(V=20\) L, and \(k=0.1000\ \mathrm{h}^{-1}\). Assume linear elimination and regular administration. Calculate the steady-state peak and trough for one, two, and three administrations per day.

For once-daily administration, \(n=1\), \(\tau=24\) h, and each dose is 300 mg. The single-dose concentration increment is \(300/20=15.00\) mg/L, while the fraction remaining at 24 hours is \(e^{-0.1000(24)}=0.09072\). Therefore,

C_{\max,ss}=\frac{15.00}{1-0.09072}=16.50\ \mathrm{mg/L}, \qquad C_{\min,ss}=16.50(0.09072)=1.497\ \mathrm{mg/L}.

The peak–trough difference is \(16.50-1.497=15.00\) mg/L, allowing for rounding. The exact difference is the 15.00 mg/L increment from the 300 mg bolus.

For twice-daily administration, \(n=2\), \(\tau=12\) h, and each dose is 150 mg. The increment is \(150/20=7.500\) mg/L, and \(e^{-0.1000(12)}=0.3012\). Thus,

C_{\max,ss}=\frac{7.500}{1-0.3012}=10.73\ \mathrm{mg/L}, \qquad C_{\min,ss}=3.233\ \mathrm{mg/L}\ \text{(using unrounded values)}.

The exact peak–trough difference is 7.500 mg/L; subtracting the displayed rounded values gives \(10.73-3.233=7.497\) mg/L, not 15.00 mg/L: each administration now contributes half the daily dose.

For three-times-daily administration, \(n=3\), \(\tau=8\) h, and each dose is 100 mg. The increment is \(100/20=5.000\) mg/L, and \(e^{-0.1000(8)}=0.4493\). Therefore,

C_{\max,ss}=\frac{5.000}{1-0.4493}=9.080\ \mathrm{mg/L}, \qquad C_{\min,ss}=9.080(0.4493)=4.080\ \mathrm{mg/L}.

Here the peak–trough difference is \(9.080-4.080=5.000\) mg/L to the shown precision. Across these hypothetical regimens, more frequent administration lowers the steady-state peak and raises the trough, while preserving the same 300 mg total daily dose.

What Changes, and What Does Not?

Under linear pharmacokinetics, the same total daily dose produces the same total daily systemic input, and hence the same daily area under the concentration–time curve (AUC), provided bioavailability and clearance are unchanged. For intravenous dosing, clearance is \(CL=kV\), so the average concentration over the day is \(D/(24CL)\). This does not imply identical concentration profiles: the peak and trough vary with the schedule even when the average exposure is the same.

The steady-state formula also shows why a difference in peak–trough fluctuation should not be confused with a difference in total dose. The change in concentration due to each individual administration is exactly \(D/(nV)\). Accumulation from earlier administrations raises both peak and trough above the levels that would follow a single isolated dose, but it does not alter the difference between the peak and trough within a steady-state interval.

Worked Example: Using Half-Life to Compare Two Frequencies

Consider a second hypothetical drug with \(D=480\) mg/day, \(V=24\) L, and a half-life of 6 h. Assume instantaneous boluses, linear elimination, and regular dosing. Compare twice-daily and four-times-daily schedules. First, \(k=\ln(2)/6=0.1155\ \mathrm{h}^{-1}\).

With two doses per day, \(\tau=12\) h, so the interval is two half-lives and \(e^{-k\tau}=e^{-(\ln 2/6)(12)}=0.2500\). Each dose is 240 mg, giving an increment of \(240/24=10.00\) mg/L. Thus,

C_{\max,ss}=\frac{10.00}{1-0.2500}=13.33\ \mathrm{mg/L}, \qquad C_{\min,ss}=13.33(0.2500)=3.333\ \mathrm{mg/L}.

With four doses per day, \(\tau=6\) h, or one half-life, and the fraction remaining is \(0.5000\). Each dose is 120 mg, giving an increment of \(120/24=5.000\) mg/L. Therefore,

C_{\max,ss}=\frac{5.000}{1-0.5000}=10.00\ \mathrm{mg/L}, \qquad C_{\min,ss}=10.00(0.5000)=5.000\ \mathrm{mg/L}.

The four-times-daily schedule has a 3.333 mg/L lower peak and a 1.667 mg/L higher trough in this calculation. The total daily dose remains 480 mg in both cases. The model predicts the direction and size of these differences under the stated assumptions; it does not account for whether either schedule is feasible or appropriate for a particular patient.

Checking a Schedule Against Concentration Limits

The equations can be used to compare regimens against specified peak and trough limits, without changing the total daily dose. A candidate passes this simple check only if its calculated peak is no greater than the peak limit and its calculated trough is no less than the trough limit. The limits and calculations must refer to compatible concentration definitions and units.

Worked Example: Checking Hypothetical Peak and Trough Limits

Use the hypothetical \(D=300\) mg/day example above, and suppose a model-based design exercise sets a peak limit of 12.0 mg/L and a trough limit of 3.0 mg/L. These limits are illustrative, not clinical recommendations. The one-dose-per-day regimen has a peak of 16.50 mg/L and trough of 1.497 mg/L, so it violates both limits.

For two doses per day, the calculated peak is 10.73 mg/L and trough is 3.233 mg/L. Since \(10.73\leq12.0\) and \(3.233\geq3.0\), this schedule satisfies both limits under the model. For three doses per day, the peak is 9.080 mg/L and trough is 4.080 mg/L, which also satisfies both. Among these candidates, twice-daily dosing is the least frequent schedule that passes the stated check. This conclusion is conditional on the model and candidates considered; it is not a general optimization result.

Diagnostics, Alternatives, and Limitations

Before interpreting these calculations, check whether the model’s assumptions are credible. The main diagnostic question is whether observed or simulated profiles are compatible with a single exponential decline between administrations and an immediate, dose-proportional concentration jump. Systematic curvature in semilog concentration-versus-time profiles, dose-dependent clearance, or delayed absorption suggests that the one-compartment bolus approximation may be inadequate. Confirm that dosing times are actually regular and that the compared regimens use the same total dose and route.

Predicted peak and trough values are especially sensitive to the assumed elimination rate and volume. Parameter uncertainty can therefore change whether a regimen appears to meet a limit. A single typical-parameter calculation does not describe between-patient variability or uncertainty in an individual’s parameters. If those matter for the decision, the comparison should use an appropriate population model or uncertainty analysis rather than treating these point predictions as certain.

For drugs administered by a route with absorption, an oral dose is not an instantaneous systemic bolus; absorption can delay and smooth the peak, and bioavailability can affect systemic input. A finite infusion likewise has a different within-interval profile. A two-compartment model can produce more than one decline phase, and nonlinear elimination can invalidate dose proportionality and the fixed accumulation formulas. In such settings, use the corresponding pharmacokinetic model rather than forcing the bolus formulas to fit.

The principal alternative to splitting a fixed daily dose is to retain fewer administrations and accept greater fluctuation, or to change the total daily dose. Those are different comparisons: increasing the total dose can raise both peak and trough as well as daily exposure, whereas dividing a fixed dose mainly smooths the profile under the assumptions here. A practical regimen must also account for administration burden, adherence, formulation, and other constraints. Concentration calculations alone cannot resolve those considerations.

Common Mistakes

Using the daily dose as the dose per administration. With \(n\) administrations, each bolus is \(D/n\), not \(D\). Substituting \(D\) into the increment overstates the concentration rise for split regimens.
Calling the peak–trough difference the peak concentration. The difference is \(D/(nV)\). The peak also includes accumulated drug remaining from prior doses.
Assuming equal daily dose means equal peaks, troughs, or profiles. Linear pharmacokinetics preserve daily exposure under the stated conditions, not the shape of the concentration curve.
Applying the equations to absorption, infusion, or nonlinear elimination without adjustment. The derivation specifically assumes instantaneous boluses and linear one-compartment elimination.

Key takeaway: For equally spaced boluses under linear one-compartment pharmacokinetics, a fixed daily dose divided into more administrations produces smaller concentration increments and shorter intervals. The steady-state peak falls and trough rises according to the fraction eliminated between doses, while the total daily dose remains fixed.

Check Your Understanding

Answer each question, then compare your reasoning with the brief solutions.

A fixed daily dose is split from one administration into two. Under the model assumptions, what happens to the dose per administration and the dosing interval?
For \(D=180\) mg/day, \(n=3\), and \(V=30\) L, calculate the concentration increment per administration.
If \(e^{-k\tau}=0.20\) and the peak concentration is 10 mg/L, what is the trough concentration and peak–trough difference?
Why can two schedules with the same total daily dose have the same daily exposure but different steady-state peaks and troughs?
Name one reason the bolus formulas may not be appropriate for an oral dosing regimen.

Solutions. (1) The dose per administration is halved, from \(D\) to \(D/2\), and the interval is halved, from 24 to 12 hours. (2) The increment is \((180/3)/30=2.000\) mg/L. (3) The trough is \(10(0.20)=2.000\) mg/L, and the peak–trough difference is \(10-2=8.000\) mg/L. (4) With linear pharmacokinetics, equal daily input and unchanged clearance preserve daily exposure, but the interval and dose increment differ, changing the concentration profile. (5) Oral absorption is not instantaneous; delayed absorption can shift and smooth the peak, so an absorption model is needed.